163 related articles for article (PubMed ID: 22250187)
21. Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma.
Ghaferi AA; Wong SL; Johnson TM; Lowe L; Chang AE; Cimmino VM; Bradford CR; Rees RS; Sabel MS
Ann Surg Oncol; 2009 Nov; 16(11):2978-84. PubMed ID: 19711133
[TBL] [Abstract][Full Text] [Related]
22. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.
Kruper LL; Spitz FR; Czerniecki BJ; Fraker DL; Blackwood-Chirchir A; Ming ME; Elder DE; Elenitsas R; Guerry D; Gimotty PA
Cancer; 2006 Nov; 107(10):2436-45. PubMed ID: 17058288
[TBL] [Abstract][Full Text] [Related]
23. The impact of shave biopsy on the management of patients with thin melanomas.
Lowe M; Hill N; Page A; Chen S; Delman KA
Am Surg; 2011 Aug; 77(8):1050-3. PubMed ID: 21944522
[TBL] [Abstract][Full Text] [Related]
24. The benefit of a sentinel lymph node biopsy and adjuvant therapy in thick (>4 mm) melanoma: multicenter, retrospective study of 291 Japanese patients.
Fujisawa Y; Otsuka F;
Melanoma Res; 2012 Oct; 22(5):362-7. PubMed ID: 22713797
[TBL] [Abstract][Full Text] [Related]
25. Sentinel lymph node status is the most important prognostic factor in patients with melanoma of the scalp.
Cappello ZJ; Augenstein AC; Potts KL; McMasters KM; Bumpous JM
Laryngoscope; 2013 Jun; 123(6):1411-5. PubMed ID: 23625541
[TBL] [Abstract][Full Text] [Related]
26. Prediction of additional lymph node positivity and clinical outcome of micrometastases in sentinel lymph nodes in cutaneous melanoma: a multi-institutional study of 450 patients in Japan.
Namikawa K; Yamazaki N; Nakai Y; Ihn H; Tomita Y; Uhara H; Takenouchi T; Kiyohara Y; Moroi Y; Yamamoto Y; Otsuka F; Kamiya H; Iizuka H; Hatta N; Kadono T
J Dermatol; 2012 Feb; 39(2):130-7. PubMed ID: 21950448
[TBL] [Abstract][Full Text] [Related]
27. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node.
Rossi CR; De Salvo GL; Bonandini E; Mocellin S; Foletto M; Pasquali S; Pilati P; Lise M; Nitti D; Rizzo E; Montesco MC
Ann Surg Oncol; 2008 Apr; 15(4):1202-10. PubMed ID: 18165880
[TBL] [Abstract][Full Text] [Related]
28. High positive sentinel node identification rate by EORTC melanoma group protocol. Prognostic indicators of metastatic patterns after sentinel node biopsy in melanoma.
van Akkooi AC; de Wilt JH; Verhoef C; Graveland WJ; van Geel AN; Kliffen M; Eggermont AM
Eur J Cancer; 2006 Feb; 42(3):372-80. PubMed ID: 16403622
[TBL] [Abstract][Full Text] [Related]
29. Predictors of positive sentinel lymph node in thin melanoma.
Yonick DV; Ballo RM; Kahn E; Dahiya M; Yao K; Godellas C; Shoup M; Aranha GV
Am J Surg; 2011 Mar; 201(3):324-7; discussion 327-8. PubMed ID: 21367372
[TBL] [Abstract][Full Text] [Related]
30. Prediction of nonsentinel lymph node metastasis in malignant melanoma.
Cadili A; Smylie M; Danyluk J; Dabbs K
J Surg Res; 2009 Jun; 154(2):324-9. PubMed ID: 19101696
[TBL] [Abstract][Full Text] [Related]
31. Role of sentinel lymph node biopsy in patients with thick (>4 mm) primary melanoma.
Jacobs IA; Chang CK; Salti GI
Am Surg; 2004 Jan; 70(1):59-62. PubMed ID: 14964550
[TBL] [Abstract][Full Text] [Related]
32. Is head and neck melanoma different from trunk and extremity melanomas with respect to sentinel lymph node status and clinical outcome?
Fadaki N; Li R; Parrett B; Sanders G; Thummala S; Martineau L; Cardona-Huerta S; Miranda S; Cheng ST; Miller JR; Singer M; Cleaver JE; Kashani-Sabet M; Leong SP
Ann Surg Oncol; 2013 Sep; 20(9):3089-97. PubMed ID: 23649930
[TBL] [Abstract][Full Text] [Related]
33. Is there a benefit to sentinel lymph node biopsy in patients with T4 melanoma?
Gajdos C; Griffith KA; Wong SL; Johnson TM; Chang AE; Cimmino VM; Lowe L; Bradford CR; Rees RS; Sabel MS
Cancer; 2009 Dec; 115(24):5752-60. PubMed ID: 19827151
[TBL] [Abstract][Full Text] [Related]
34. Influence of sentinel lymph node tumor burden on survival in melanoma.
Francischetto T; Spector N; Neto Rezende JF; de Azevedo Antunes M; de Oliveira Romano S; Small IA; Gil Ferreira C
Ann Surg Oncol; 2010 Apr; 17(4):1152-8. PubMed ID: 20087785
[TBL] [Abstract][Full Text] [Related]
35. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
[TBL] [Abstract][Full Text] [Related]
36. Sentinel lymph node status is the most important prognostic factor for thick (> or = 4 mm) melanomas.
Gutzmer R; Satzger I; Thoms KM; Völker B; Mitteldorf C; Kapp A; Bertsch HP; Kretschmer L
J Dtsch Dermatol Ges; 2008 Mar; 6(3):198-203. PubMed ID: 18093216
[TBL] [Abstract][Full Text] [Related]
37. Lymphatic invasion detected by D2-40/S-100 dual immunohistochemistry does not predict sentinel lymph node status in melanoma.
Petitt M; Allison A; Shimoni T; Uchida T; Raimer S; Kelly B
J Am Acad Dermatol; 2009 Nov; 61(5):819-28. PubMed ID: 19836642
[TBL] [Abstract][Full Text] [Related]
38. [Tumour regression is not predictive for higher risk of sentinel node involvement in thin melanomas (Breslow thickness < or = 1 mm)].
Kramkimel N; Maubec E; Boitier F; Cavalcanti A; Beldi M; Mamelle G; Kolb F; Duvillard P; Avril MF
Ann Dermatol Venereol; 2010 Apr; 137(4):276-80. PubMed ID: 20417360
[TBL] [Abstract][Full Text] [Related]
39. Sentinel lymph node status in melanoma: a valuable prognostic factor?
Topar G; Eisendle K; Zelger B; Fritsch P
Br J Dermatol; 2006 Jun; 154(6):1080-7. PubMed ID: 16704637
[TBL] [Abstract][Full Text] [Related]
40. [Important prognostic significance of a sentinel-node biopsy in patients with malignant melanoma].
Keijzer R; Bril H; van der Loo EM; de Graaf PW
Ned Tijdschr Geneeskd; 2004 May; 148(18):884-8. PubMed ID: 15152391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
